Visen Pharmaceuticals

Amid a sweeping tightening of securities regulatory policies since late 2023, there has been a dearth of initial public offerings for bioventures in the Chinese mainland. But Hong Kong has just welcom

Chinook Therapeutics, Inc. is developing a pair of drugs – an oral tablet and a monoclonal antibody – for IgA nephropathy, with potentially pivotal data expected for the oral drug in 2023. The Vancou

Ascendis Pharma A/S obtained its first product approval on 25 August with a US Food and Drug Administration thumbs-up for its weekly injectable formulation of somatropin in pediatric growth hormone d

Biopharmaceutical companies raised $19.5bn in venture capital through the third quarter of 2020 and now Pitchbook and the National Venture Capital Association (NVCA) have revealed that the industry br